Loading...
•
Dec 31, 2020
Stryker Q4 2020 Earnings Report
Stryker's Q4 2020 results reflected resilience amidst COVID-19 challenges, with net sales increasing by 3.2% and adjusted EPS rising by 12.9%.
Key Takeaways
Stryker reported a 3.2% increase in net sales to $4.3 billion for Q4 2020. Despite challenges from the COVID-19 pandemic, the company's adjusted EPS increased by 12.9% to $2.81. The Wright Medical integration is off to a strong start, and innovation continues across the company.
Net sales increased 3.2% to $4.3 billion.
Organic net sales decreased 1.1%.
Adjusted EPS increased 12.9% to $2.81.
The Wright Medical integration is off to a strong start.
Revenue by Segment
Forward Guidance
Stryker expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019 and adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
Positive Outlook
- Expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019
- Expects adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
- Includes the previously announced 10 cents of dilution driven by the acquisition of Wright Medical for the full year.
- Assumes an ongoing recovery in our key geographies leading to more normalized elective procedure levels during the second quarter of 2021.
- Expect EPS will be modestly favorable for the full year if foreign currency exchange rates hold near current levels.
Challenges Ahead
- The impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties
- Unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...